Evidence map›Paper›PMID 34729023›Full record

ArticleCancer management and research2021

The Association of Clinical Outcomes with Posttreatment Changes in the Relative Eosinophil Counts and Neutrophil-to-Eosinophil Ratio in Patients with Advanced Urothelial Carcinoma Treated with Pembrolizumab.

Nobuki Furubayashi, Akinori Minato, Takahito Negishi, Naotaka Sakamoto, Yoohyun Song, Yoshifumi Hori, Toshihisa Tomoda, Shingo Tamura, Kentaro Kuroiwa, Narihito Seki and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cancer management and research, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
17citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

17 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Observational
  5. Article
  6. Article
  7. Review
  8. Review
  9. Article
  10. Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Article
  17. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Nobuki FurubayashiDepartment of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.ORCID 0000-0001-9159-493X
Akinori MinatoDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.
Takahito NegishiDepartment of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.
Naotaka SakamotoDepartment of Urology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Yoohyun SongDepartment of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan.
Yoshifumi HoriDepartment of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
Toshihisa TomodaDepartment of Urology, Oita Prefectural Hospital, Oita, Japan.ORCID 0000-0002-9346-1900
Shingo TamuraDepartment of Medical Oncology, National Hospital Organization Kyushu Medical Center, Fukuoka, Japan.
Kentaro KuroiwaDepartment of Urology, Miyazaki Prefectural Miyazaki Hospital, Miyazaki, Japan.
Narihito SekiDepartment of Urology, Kyushu Central Hospital of the Mutual Aid Association of Public School Teachers, Fukuoka, Japan.
Naohiro FujimotoDepartment of Urology, University of Occupational and Environmental Health, Kitakyushu, Japan.ORCID 0000-0002-5256-6415
Motonobu NakamuraDepartment of Urology, National Hospital Organization Kyushu Cancer Center, Fukuoka, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTo evaluate the association of clinical outcomes with posttreatment changes in the relative eosinophil count (REC) and neutrophil-to-eosinophil ratio (NER) in patients with advanced urothelial cancer (UC) treated with pembrolizumab. MATERIALS AND

methodsWe retrospectively analyzed 105 patients with advanced UC who received pembrolizumab after the failure of platinum-based chemotherapy. The REC and NER before and three weeks after pembrolizumab were recorded. A receiver operating characteristic curve was used to determine the optimal cut-off values for analyzing the risk.

resultsThere were no significant differences in the overall survival (OS) between the REC ≥4.8% and <4.8% groups and the NER ≥13.7 and <13.7 groups before pembrolizumab (p=0.997 and 0.669, respectively). However, a significant difference in the OS was confirmed between the increased and decreased REC groups and between the decreased and increased NER groups at 3 weeks after pembrolizumab (p<0.001 and 0.002, respectively). Multivariate analyses revealed that an Eastern Cooperative Oncology Group Performance Status ≥2 (P=0.003), albumin <3.7 g/dl (p=0.002), LDH >246 U/L (p=0.011), disease site ≥3 organs (p=0.019), decreased posttreatment REC (3 weeks later) (p=0.002) and increased posttreatment NER (3 weeks later) (p=0.022) were independent prognostic factors for a worse OS.

conclusionAn increased REC and decreased NER after pembrolizumab may be significant early predictive markers of improved clinical outcomes in patients with advanced UC receiving pembrolizumab.

Indexed as

eosinophilneutrophil-to-eosinophil ratiopembrolizumaburothelial carcinoma

Identifiers

PMID34729023
PMCPMC8554313

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.